View Single Post
Old 03-06-2009, 08:58 AM   #8
runtolive
Senior Member
 
Join Date: Nov 2007
Posts: 210
t-dm1

they have closed the phase 2 third line study.. which was much more open..

genentech is on the homestretch to approval.. so now they are tightening the requirements to get into further studies..

they have the pivotal phase 3 head to head with tykerb / xeloda vs tdm1 280 pts in each arm.. should be enrolled within 9-12 months

also have first line trial in phase 2 100 pts vs taxotere for newly diagnosed MBC pts..

soon to begin will be a phase 1 trial with tdm1 + pertuz..this will start by june.. supposed to be farely nonrestrictive.
runtolive is offline   Reply With Quote